Adage Capital Partners
KTTA icon

Adage Capital Partners’s Pasithea Therapeutics KTTA Stock Holding History

Adage Capital Partners’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.56M Hold
2,100,000
– – ﹤0.01% 853
2025
Q4 		$2.71M Buy
+2,100,000
New +$1.85M ﹤0.01% 817

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners's KTTA Position: Q1 2026 in Review

Adage Capital Partners held its Pasithea Therapeutics (KTTA) position steady in Q1 2026 at 2,100,000 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Adage Capital Partners first reported a position in KTTA in Q4 2025 and has held it in 2 quarters since. The position peaked at $2.71M in Q4 2025. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Adage Capital Partners held 2,100,000 shares of Pasithea Therapeutics worth $1.56M as of Q1 2026.
  • Adage Capital Partners left its Pasithea Therapeutics share count unchanged in Q1 2026.
  • Pasithea Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q1 2026, its #853 holding.
  • Adage Capital Partners first reported a position in Pasithea Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Adage Capital Partners's Pasithea Therapeutics position peaked at $2.71M in Q4 2025.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.